← Back to Home

Giving Covalent Drugs a More Restrained “Warhead”: Bicyclobutane Chemistry Preserves Antitumor Activity in Mice

Researchers replaced traditional acrylamide with a tunable bicyclobutane group, enabling a redesigned lung cancer drug to reduce unintended protein binding while maintaining tumor control in mice; however, there is still a long way to go before any safety advantage in humans can be demonstrated.

By SURL BioNews

The strength of covalent drugs is also what makes them most difficult to control: once they form a stable chemical bond with a target protein, their effects can last longer; but if their reactivity is not properly controlled, they may also modify proteins they should not affect. A team from Moffitt Cancer Center and the University of South Florida has now introduced a new “chemical warhead” designed to narrow the scope of such unintended effects without sacrificing antitumor activity.

Published in *Science*, the study centers on highly strained bicyclobutane rings and establishes a sulfur(IV) reagent platform that can be attached to drug molecules at a late stage of development to generate sulfonyl and sulfonimidoyl bicyclobutanes. The study showed that these groups preferentially react with cysteine and that structural adjustments can alter the rate of the strain-release reaction, allowing developers not only to choose whether a covalent bond forms, but also to fine-tune the conditions and speed of its formation.

The practical value of this design is that it does not require rebuilding the entire drug scaffold from scratch. The researchers replaced the original acrylamide groups in several approved or experimental covalent inhibitors, including dacomitinib, which is used for certain non-small cell lung cancers. The redesigned version still inhibited its intended cancer target, but proteomic analysis showed that its interactions with unintended proteins were markedly reduced.

The team then compared the two drugs in mice bearing human lung tumors. According to results released by the research institution, the new version controlled tumor growth to a degree comparable to the original drug, achieved better drug exposure in vivo, and showed no evident toxicity during the study. This means the new chemistry is more than a demonstration of selectivity in a test tube, with preliminary whole-animal evidence now supporting it.

However, “less off-target binding” cannot be directly equated with “safer for patients.” Mouse studies are limited in duration, sample size, and the toxicities they can detect. Whether higher systemic exposure can widen the therapeutic window or instead introduce different risks will also require comprehensive pharmacokinetic studies, long-term toxicology, and testing in multiple species. For now, the dacomitinib derivative should be viewed as a platform-validation tool rather than a new drug ready to replace existing therapies.

The broader significance of this work may lie in the drug development process itself. If bicyclobutane warheads can maintain predictable reactivity across more scaffolds, targets, and disease models, development teams may be able to replace reactive groups even when a drug candidate is already relatively mature, without having to overhaul the entire molecular design. However, the protein environment in humans is far more complex than experimental systems, and the researchers also emphasized that the technology must undergo further preclinical validation before human trials can be considered.

References

  1. Medical Xpress
  2. PubMed
  3. Moffitt Cancer Center via Newswise